Valeant Pharmaceuticals Announces 2014 Annual Meeting Results

LAVAL, Quebec, May 21, 2014 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2014 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below:

Name		For		Withheld		Broker Non-Votes
Ronald H. Farmer		251,288,239		908,255		21,179,009
Colleen A. Goggins		251,712,817		483,677		21,179,009
Robert A. Ingram		249,639,221		2,557,273		21,179,009
Anders Lonner		251,650,643		545,851		21,179,009
Theo Melas-Kyriazi		251,423,599		772,895		21,179,009
J. Michael Pearson		246,575,385		5,621,109		21,179,009
Robert N. Power		250,186,656		2,009,838		21,179,009
Norma A. Provencio		251,604,073		592,421		21,179,009
Howard B. Schiller		238,521,290		13,675,204		21,179,009
Katharine B. Stevenson		250,315,363		1,881,131		21,179,009

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2015 annual meeting of shareholders; and approved the 2014 Omnibus Incentive Plan and the ratification and approval of the grants of 320,033 share units and 180,000 options which were made subject to the shareholder approval of the 2014 Plan.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
[email protected]

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

SOURCE: Valeant Pharmaceuticals International, Inc.

http://www.valeant.com

http://photos.prnewswire.com/prnh/20101025/LA87217LOGO